Drug intelligence / Profile preview

CPI-003

Development stage: Unknown
Lead developer: Curadel
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CPI-003 is a zwitterionic targeted alpha therapy (TAT) developed by Curadel Pharma. It is designed as a potential best-in-class radiopharmaceutical for the treatment of challenging rare cancers. The drug leverages Curadel’s proprietary zwitterionic technology platform, which aims to prevent tumor regrowth and resistance while minimizing collateral damage to healthy tissues. CPI-003 represents a novel approach in radiopharma, focusing on pan-tumor applications and targeting mechanisms that may help overcome tumor resistance[1][2].

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on CPI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPI-003.

Explore the full profile